



MedDRA & WHODrug User Group Meeting

February 6, 2018 – Novotel Bengaluru Techpark Hotel, Bangalore, India

8:00-9:00	Registration	
9:00-9:30	Opening & introduction	Damon Fahimi, UMC and Pat Revelle, MedDRA MSSO
9:30-10:00	Keynote: Coding – What's the point?	Birgitta Grundmark, UMC
10:00-11:15	Report from UMC	Anna Mattsson, Damon Fahimi and Malin Fladvad, UMC
11:15-11:45	Coffee & tea break	
11:45-13:00	Report from MedDRA MSSO	Pat Revelle, MedDRA MSSO
13:00-14:00	Lunch	
14:00-15:30	Application of MedDRA and WHODrug to a clinical trial – an interactive session	Anna Baumgarten, UMC and Jane Knight, MedDRA MSSO
15:30-16:00	Coffee & tea break	
16:00-16:25	Implementation of the WHODrug B3-format	Dhanya Poullose, IQVIA
16:25-16:50	Overview and importance of common terminology criteria for adverse events (CTCAE) in oncology trials	Amreen Taj and Rajiv Rai, Chiltern
16:50-18:05	MedDRA & WHODrug Panel discussion	<u>Moderator</u> Shawn Davis Raj, eClinical Solutions India <u>Panelists:</u> Amit Kulkarni, Novartis Healthcare Manoj Shanmugasundaram, IQVIA Ranganath Nagarjuna, Chiltern Shubhadeep Sinha, Hetero Drugs
18:05-18:30	Open Q&A session, wrap-up and closing remarks	All presenters
18:30-19:15	Drink reception	
19:15	Networking dinner	

This event is co-hosted by the MedDRA MSSO and the Uppsala Monitoring Centre (UMC).

For any questions, please contact:
WHODrug@who-umc.org
or
mssohelp@meddra.org